<SEC-DOCUMENT>0001564590-20-031884.txt : 20200707
<SEC-HEADER>0001564590-20-031884.hdr.sgml : 20200707
<ACCEPTANCE-DATETIME>20200707073536
ACCESSION NUMBER:		0001564590-20-031884
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200707
FILED AS OF DATE:		20200707
DATE AS OF CHANGE:		20200707

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zai Lab Ltd
		CENTRAL INDEX KEY:			0001704292
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38205
		FILM NUMBER:		201015239

	BUSINESS ADDRESS:	
		STREET 1:		4560 JINKE ROAD
		STREET 2:		BLDG. 1, 4F, PUDONG
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862161632588

	MAIL ADDRESS:	
		STREET 1:		4560 JINKE ROAD
		STREET 2:		BLDG. 1, 4F, PUDONG
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zlab-6k_20200707.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
zlab-6k_20200707.htm
</title>
</head>
<!-- NG Converter v5.0.2.46 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 6-K </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF FOREIGN PRIVATE ISSUER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO RULE 13A-16 OR 15D-16</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the month of July 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission Filing Number: 001-38205</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ZAI LAB LIMITED</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Translation of registrant&#8217;s name into English)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4560 Jinke Road, Bldg. 1, 4F, Pudong, Shanghai, China 201210</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive office) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:66.67%;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form 20-F <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></font> Form 40-F <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">License Agreement</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 7, 2020, Zai Lab (Shanghai) Co., Ltd., a subsidiary of Zai Lab Limited (&#8220;Zai&#8221;), entered into a License Agreement (the &#8220;License Agreement&#8221;) with Turning Point Therapeutics, Inc. (&#8220;Turning Point&#8221;), pursuant to which Turning Point granted Zai exclusive rights to develop and commercialize products containing Turning Point&#8217;s drug candidate, repotrectinib (the &#8220;Products&#8221;), in Mainland China, Hong Kong, Macau and Taiwan (each, a &#8220;region&#8221; and collectively, the &#8220;Territory&#8221;). Turning Point retains exclusive rights to, among other things, develop, manufacture and commercialize the Products outside the Territory. Turning Point will supply or have supplied to Zai the Products for use in the Territory pursuant to a supply agreement for agreed upon consideration, except that Zai has the right, at its election, to package and label the Products in or outside the Territory for use in the Territory.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the License Agreement, Turning Point will receive an upfront cash payment of $25.0&#160;million and will be eligible to receive up to $151.0&#160;million in development and sales milestone payments, consisting of up to $46.0&#160;million of development milestones and up to $105.0&#160;million of sales milestones. In addition, during the term of the License Agreement, Zai will pay Turning Point tiered percentage royalties ranging from mid-to-high teens on annual net sales of the Products in the Territory, subject to adjustments in specified circumstances.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the License Agreement, Zai will be responsible for conducting the development and commercialization activities in the Territory related to the Products at Zai&#8217;s own expense, subject to limited exceptions pursuant to which Turning Point may be responsible for the cost. Turning Point will be responsible for global clinical studies of the Products, including the portions that may be conducted in the Territory, at Turning Point&#8217;s expense, except that Zai will participate in global clinical studies of the Products through clinical trial sites in the Territory as agreed as of the effective date of the License Agreement and may, at Zai&#8217;s election, participate in future global clinical studies of the Products through clinical trial sites in the Territory, in each case at Zai&#8217;s expense.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to specified exceptions, during the term of the License Agreement, Zai has agreed that neither it nor its affiliates, its licensees and its sublicensees will conduct any development, manufacturing and commercialization activities with specified products that would compete with the Products in or outside the Territory, and Turning Point has agreed that neither it nor its affiliates, its licensees and its sublicensees of Products will conduct any development, manufacturing and commercialization activities with such competing products in the Territory, other than manufacturing activities in support of activities outside the Territory. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the License Agreement, Zai will have a first right to negotiate a license in the Territory to up to two additional drug candidates in Turning Point&#8217;s pipeline, if Turning Point seeks to license the right to commercialize any such drug candidate in a territory that primarily includes one or more regions in the Territory (but excluding a proposed worldwide license).</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the License Agreement, if Turning Point is acquired in a change of control transaction, until such time when Zai files the first regulatory approval application for the first Product in the Territory, Turning Point&#8217;s acquirer will have a first right to negotiate with Zai the right to co-commercialize the Products in the Territory.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>The License Agreement will continue in effect until expiration of the last royalty term for a Product in any region in the Territory, where the royalty term for a Product in a region continues until the later of (i)&#160;the date of the last-to-expire valid claim within Turning Point&#8217;s patent rights that covers the Product in such region in the Territory; (ii)&#160;the expiry of the regulatory exclusivity for such Product in such region; or (iii)&#160;the close of business of the day that is exactly 10&#160;years after the date of the first commercial sale of such Product in such </p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">region. Subject to the terms of the License Agreement, Zai may terminate the License Agreement for convenience by providing written notice to Turning Point, which termination will be effective following a prescribe</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d notice period. In addition, Turning Point may terminate the License Agreement under specified circumstances if Zai or certain other parties challenge Turning Point&#8217;s patent rights. Either party may terminate the License Agreement for the other party&#8217;s un</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cured material breach of the License Agreement, with a customary notice and cure period, for the other party&#8217;s insolvency or if the other party is acquired in a change of control transaction and the acquirer is engaged in activities with a competing produc</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t that is not divested or discontinued within a specified period. After termination (but not natural expiration), other than certain terminations by Zai for cause, Turning Point is entitled to retain a worldwide and perpetual license from Zai to exploit th</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e Products.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing description of the License Agreement is only a summary and is qualified in its entirety by reference to the License Agreement, a copy of which will be filed as an exhibit to Zai&#8217;s next periodic report.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zai has filed as an exhibit to this Form&#160;6-K&#160;a press release dated July 7, 2020 announcing the entry into the License Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:504pt;;">
<tr>
<td style="width:54pt;"></td>
<td style="width:31.5pt;"></td>
<td style="width:418.5pt;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="zlab-ex991_6.htm"><font style="text-decoration:underline;">Press release issued July 7, 2020.</font></a></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:53.33%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ZAI LAB LIMITED</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:104.16%;">
<tr>
<td valign="middle"  style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle"  style="width:83.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:51.2%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:7.16%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&#160;</p></td>
<td valign="bottom"  style="width:34.28%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Samantha Du</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:51.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&#160;</p></td>
<td valign="bottom"  style="width:34.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Samantha Du</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:51.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&#160;</p></td>
<td valign="bottom"  style="width:34.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:51.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: July 7, 2020</p></td>
<td valign="bottom"  style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:34.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>zlab-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
zlab-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.46 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:51.39%;"><img src="gzkpjftmi0rk000001.jpg" title="" alt="" style="width:151px;height:52px;"><img src="gzkpjftmi0rk000002.jpg" title="" alt="" style="width:294px;height:78px;"></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-right:0.23%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">TURNING POINT THERAPEUTICS AND ZAI LAB ANNOUNCE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">EXCLUSIVE LICENSE AGREEMENT FOR REPOTRECTINIB IN GREATER CHINA</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;">Zai Lab Granted Exclusive Rights to Develop and Commercialize Repotrectinib in Greater China</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;">Turning Point to Receive $25 Million Upfront, Potential for Future Milestones of up to $151 Million and Royalties</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;"><a name="_Hlk43372319"></a>TRIDENT-1 Phase 2 Registrational Study of Repotrectinib to Open Additional Sites in Greater China</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SAN DIEGO and SHANGHAI,&#160;July 7, 2020<font style="font-weight:normal;"> &#8211;&#160;Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced an exclusive license agreement for the development and commercialization of Turning Point&#8217;s lead drug candidate, repotrectinib, in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, Zai Lab will obtain exclusive rights to develop and commercialize repotrectinib in Greater China and Turning Point Therapeutics will receive a $25 million upfront payment, with potential to receive up to an additional $151 million in development, regulatory and sales-based milestone payments. Turning Point will also be eligible to receive mid-to-high teen royalties based on annual net sales of repotrectinib in Greater China.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;With more than 700,000 newly diagnosed lung cancer patients every year in Greater China, and the development and commercialization capabilities Zai Lab have shown over time in the region, we view Zai Lab as the ideal partner to help expand the potential reach of repotrectinib,&#8221; said Athena Countouriotis, M.D., President and Chief Executive Officer of Turning Point Therapeutics. &#8220;Our collaboration with Zai Lab is a strategic step to potentially accelerate the development of repotrectinib in Greater China.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk43372337"></a>Zai Lab anticipates opening additional sites for the TRIDENT-1 Phase 2 registrational clinical study of repotrectinib. The ongoing study is currently active in 11 countries globally and enrolling patients with <font style="font-style:italic;">ROS1</font>-positive advanced non-small cell lung cancer (NSCLC) and <font style="font-style:italic;">NTRK</font>-positive solid tumors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>&#8220;We are very pleased to enter into this agreement with Turning Point Therapeutics. Repotrectinib is highly synergistic with Zai&#8217;s existing pipeline and further strengthens our disease area strongholds across most common tumor types in China, particularly in lung </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cancer</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> look</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ing</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> forward </font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bring</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ing</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this </font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential best</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">class agent in </font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">front-line</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> setting </font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and for patients previously treated with an approved </font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tyrosine kinase inhibitor (TKI)</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> where there are no approved targeted therapies</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> said Samantha Du</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ph.D.</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="Background-color:#FFFFFF;">Founder, Chairwoman and Chief Executive Officer </font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of Zai Lab. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;In China, there is only one approved targeted therapy for patients with advanced <font style="font-style:italic;">ROS1</font>-positive lung cancer and despite its efficacy, most patients eventually acquire resistance,&#8221; said Dr. Lu Shun, Director of Chinese Lung Cancer Association. &#8220;The unmet need in the <font style="font-style:italic;">ROS1</font>-positive lung cancer patient population is significant. The preliminary clinical activity and safety data generated to date for repotrectinib represent a promising clinical profile. If approved, repotrectinib has the potential to be the standard of care for <font style="font-style:italic;">ROS1</font>-positive patients with advanced non-small cell lung cancer in China.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FEFEFE;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About Repotrectinib</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repotrectinib is an investigational next-generation TKI designed to effectively target ROS1 and TRK A/B/C with potential to treat TKI-na&#239;ve or -pretreated patients. <font style="font-style:italic;">ROS1</font>&#160;rearrangement is estimated to be an oncogenic driver in approximately 2 to 3 percent of patients with advanced NSCLC in China, and NTRK is estimated to be an oncogenic driver in approximately 0.5 percent of patients with other advanced solid tumors in China.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilizing a 22 July 2019 data cut-off, data from the Phase 1 portion of TRIDENT-1 demonstrated the potential for repotrectinib to be best-in-class for the treatment of <font style="font-style:italic;">ROS1</font>-positive advanced NSCLC in patients who were not previously treated with a TKI, with a 91 percent overall response rate by blinded independent central review, a median duration of response of 23.1 months, a median progression-free survival of 24.6 months, and a generally well-tolerated adverse-event profile.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More information about the ongoing TRIDENT-1 study of repotrectinib may be found by searching clinical trial identifier NCT03093116 at<font style="Background-color:#FFFFFF;color:#2C3E50;">&#160;</font><font style="Background-color:#FFFFFF;text-decoration:underline;">https://clinicaltrials.gov</font><font style="Background-color:#FFFFFF;color:#2C3E50;">.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk31377031"></a>About Zai Lab<font style="color:#504D4D;font-weight:normal;"><br /></font><font style="font-weight:normal;">Zai Lab&#160;(NASDAQ:ZLAB) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in&#160;China&#160;and around the world. To quickly target the large, fast-growing segments of China&#8217;s pharmaceutical market and address unmet medical needs, Zai Lab&#8217;s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates.&#160;Zai Lab&#160;has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas. Zai Lab&#8217;s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional information about the company, please visit&#160;<font style="text-decoration:underline;color:#000000;">www.zailaboratory.com</font>&#160;or follow us at&#160;<font style="text-decoration:underline;color:#000000;">www.twitter.com/ZaiLab_Global</font>.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FEFEFE;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About Turning Point Therapeutics Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>Turning Point Therapeutics&#160;is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company&#8217;s lead drug candidate, repotrectinib, is a next-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-na&#239;ve and pre-treated patients. The company&#8217;s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in </font><font style="font-style:italic;">MET</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; TPX-0046, targeting RET and SRC, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in </font><font style="font-style:italic;">RET</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; and TPX-0131, a next-generation ALK inhibitor in IND-enabling studies. Turning Point&#8217;s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit </font><font style="text-decoration:underline;color:#000000;">www.tptherapeutics.com</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Zai Lab Forward Looking Statements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains statements about future expectations, plans and prospects for Zai Lab, including, without limitation, statements regarding the prospects of and plans for commercializing repotrectinib in mainland China, Hong Kong, Macau and Taiwan. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking statements are based on Zai Lab's expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) Zai Lab&#8217;s ability to obtain additional future funding, (2) Zai Lab&#8217;s results of clinical and pre-clinical development of its drug candidates, (3) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of Zai Lab&#8217;s drug candidates, (4) Zai Lab&#8217;s ability to generate revenue from its drug candidates, (5) the effects of the novel coronavirus (COVID-19) pandemic on general economic, regulatory and political conditions and (6) other factors discussed in Zai Lab's Annual Report on Form 20-F for the fiscal year ended December 31, 2019, filed on April 29, 2020, and its other filings with the Securities and Exchange Commission. Zai Lab anticipates that subsequent events and developments will cause Zai Lab&#8217;s expectations and assumptions to change and undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing Zai Lab&#8217;s views as of any date subsequent to the date of this press release.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Turning Point Therapeutics Forward Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>Statements contained in this press release regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Turning Point Therapeutics&#8217; drug candidate repotrectinib, the results, conduct, and progress of Turning Point Therapeutics&#8217; TRIDENT-1 clinical study of repotrectinib, including the ability of <font style="color:#000000;">Zai Lab to open additional sites and the potential to accelerate the development of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">repotrectinib </font><font style="color:#000000;">in Greater China</font><font style="color:#000000;">, </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the ability to </font><font style="color:#000000;">expand the potential reach of repotrectinib to patients in Greater China,</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the potential to receive </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">milestone and royalty payments from Zai Lab</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as &#8220;plans&#8221;, &#8220;will&#8221;, &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;goal,&#8221; &#8220;potential&#8221; and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics&#8217; current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics&#8217; business in general, </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point&#8217;s business, </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the other risks described in Turning Point Therapeutics&#8217; filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONTACTS:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Zai Lab</font><font style="font-weight:normal;"><br />Billy Cho, CFO<br />+86 137 6151 2501 <br /></font><font style="text-decoration:underline;font-weight:normal;color:#000000;">billy.cho@zailaboratory.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media: Ryo Imai / Robert Flamm, Ph.D.<br />Burns McClellan, on behalf of Zai Lab<br />212-213-0006 ext. 315 / 364</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">rimai@burnsmc.com</font><font style="color:#000000;"> / </font><font style="text-decoration:underline;">rflamm@burnsmc.com</font><font style="color:#000000;text-decoration:underline;"> </font><font style="text-decoration:underline;color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors: Pete Rahmer / Mike Zanoni<br />Endurance Advisors, on behalf of Zai Lab<br />415-515-9763 / 610-442-8570</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">prahmer@enduranceadvisors.com</font><font style="color:#000000;"> / </font><font style="text-decoration:underline;">mzanoni@enduranceadvisors.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Turning Point Therapeutics</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jim Mazzola</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">jim.mazzola@tptherapeutics.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">858-342-8272</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gzkpjftmi0rk000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkpjftmi0rk000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #D >D# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH+ #-,$I;H*
M 'T4U),C)I0P/2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B@G R::90HR10
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M1%'J3_\ 7J92C"-Y&^%PM?&5XT:,7*4G9);MGJ@.>I_.C;GN/RK\U#_P<O\
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M\$T!P.@K\P?^(E_]G_\ Z)-XA_[X3_XJGVG_  <Q?L\LQ%U\)O$BK_>1$/\
M[-4_VI@/YT:R\+..HQO]3E^'^9^G@ ;G-)R3BOSP^&/_  <8_L@>-O$]OH'B
M'1M<T&&=MOV^_MU\E&/3)4FON[X?_$SPA\4/#-KXP\$ZU;ZAIU[$LEO=6\@9
M74C/:NJCBL/B/X<D_F?-9QPSGN0V6/P\J=]KHZ2BHEF8_*RU*#D9KH/""BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AEP7XJ:H9CALF@#\NO\
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M9O\ OFNSZG3^K.C.[\WO_2/AL1Q[F3XE6<8.$:,TDN6*T?JNMS^;75_V%O\
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M%>-LXX1Q$JN%:DIJTHO6,C^9?4/A;_P4<\/WLFCW&B_$^.2W?8Z1W%X5!'&
M0V,5&/ ?_!1$#YM+^*>?^NU[_C7],K:98[BS6T?_ 'R*0:?8M]ZTC_[X%>?_
M &+&.U61^B_\1JYEKEE%OJ^5?Y'\S8\!?\%#^O\ 9?Q4_P"_U[_C49\ ?\%$
M]_.E?%/V_>WO^-?TS_V?I^['V6/_ +Y%*-.T]#S;QG_@ J7DO_3V0O\ B-4>
MF64?_ 5_D?S>^!/^"?G_  44_:>U"VM+SP!XJO+<7 B^U^)+F79!GO\ O3D
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M,8U)/XFNS UJE23A)WM;;;4^)XVR7+,KP=*IA*=E-M7ZZ6_S.W0_+4=P3LW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gzkpjftmi0rk000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkpjftmi0rk000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !/ 2<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
